Online inquiry

IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3791MR)

This product GTTS-WQ3791MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor VIIa substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000131.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2155
UniProt ID P08709
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3791MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7461MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ8282MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ1968MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ11875MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ6098MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ10013MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ11674MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ7204MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW